RxDoctor Payments Data

Kandra Dodd, APRN

Family · McAlester, OKNPI 1003393778

Payments from drug & device makers

$1,365in general payments, 2019–2025

Across 92 payments — averaging $14.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$572
  • AbbVie$254
  • Lilly USA, LLC$205
  • Bayer$70
  • Ardelyx, Inc.$52
  • Otsuka America Pharmaceutical, Inc.$43
  • plus $169 from 8 others

What the payments were for

  • Food & beverage$1,365100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,365 in reported general payments places this provider in the 75th percentile of 2,026 family providers in Oklahoma.

See all family providers in Oklahoma

Medicare billing

Part B allowed, 2024
$38,343
Medicare patients
129
Services billed
669

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide179$232,270
OzempicSemaglutide129$169,652
JardianceEmpagliflozin34$37,689
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$34,324
LinzessLinaclotide44$31,298
EliquisApixaban13$16,571
ZubsolvBuprenorphine Hcl/Naloxone Hcl11$14,251
WegovySemaglutide11$13,959
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl43$7,608
Dexlansoprazole DrDexlansoprazole24$6,811
Humalog Kwikpen U-100Insulin Lispro11$1,981
Tolterodine Tartrate ErTolterodine Tartrate11$1,661
ValacyclovirValacyclovir Hcl27$1,337
Albuterol Sulfate HfaAlbuterol Sulfate50$1,273
Omeprazole66$1,125

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$205$232,270179 claims
Novo NordiskOzempic, Wegovy$572$183,612140 claims
GSKTrelegy Ellipta$16$34,32435 claims
AbbVieLinzess, Synthroid$254$32,41458 claims
PfizerEliquis$33$16,57113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,026 family providers in Oklahoma.

Other family in McAlester

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →